To improve the transcriptional activity of CEA promoter and maintaining its cancer-targeting specificity, we took advantage of the high NF-κB activity in CRC cell lines and designed a novel NF-κB-CEA chimeric enhancer–promoter system (Figure 1). This evidence concerns the gene NFKB1 and cancer.